Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep Learning

Launched by SUN YAT-SEN UNIVERSITY · Sep 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how to predict a painful condition called severe oral mucositis, which can occur in patients receiving chemotherapy and radiation treatment for nasopharyngeal carcinoma, a type of throat cancer. Researchers are using advanced computer technology, specifically a method called deep learning, to analyze treatment plans and better understand which patients are at higher risk for developing this side effect. The goal is to improve the accuracy of these predictions, which could help doctors plan treatments that reduce the chances of complications and improve the quality of life for patients.

To participate in this study, patients must have a recent diagnosis of non-keratotic nasopharyngeal carcinoma and be receiving their first round of a specific type of radiation therapy called intensity-modulated radiation therapy (IMRT). Patients who have previously received radiation, had surgery for their cancer, or have a history of other cancers are not eligible. Those who join the study can expect to undergo assessments related to their treatment to help researchers gather important information. Overall, this study aims to enhance treatment planning and minimize the impact of severe oral mucositis on patients' lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Initial diagnosis, pathological histological diagnosis, the pathological type is non-keratotic carcinoma (according to the WHO pathological classification).
• • Initial intensity-modulated radiotherapy (Intensity modulated radiation therapy, IMRT).
• • No previous radiotherapy was received.
• Exclusion Criteria:
• • Patients with recurrent nasopharyngeal carcinoma.
• • Radiotherapy plan cannot be obtained.
• • Previous history of malignancy; previous radiotherapy.
• • The primary lesion and cervical metastatic lesions have received surgical treatment (except for diagnostic treatment).